UOC
CRVS icon

UBS O'Connor’s Corvus Pharmaceuticals CRVS Stock Holding History

UBS O'Connor’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,850
Closed -$66.3K – 402
2025
Q1 		$66.3K Sell
20,850
-19,150
-48% -$90.2K ﹤0.01% 275
2024
Q4 		$214K Buy
+40,000
New +$299K 0.01% 328
2016
Q3 		– Sell
-20,000
Closed -$285K – 432
2016
Q2 		$285K Sell
20,000
-97,300
-83% -$1.31M 0.01% 362
2016
Q1 		$1.7M Buy
+117,300
New +$1.68M 0.02% 334

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS O'Connor's CRVS Position: Q2 2025 in Review

UBS O'Connor sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 20,850 shares — an estimated $66.3K sold.

UBS O'Connor first reported a position in CRVS in Q1 2016 and held it in 4 quarters. The position peaked at $1.7M in Q1 2016. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

  • UBS O'Connor reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 20,850 Corvus Pharmaceuticals shares in Q2 2025, an estimated $66.3K.
  • UBS O'Connor first reported a position in Corvus Pharmaceuticals in Q1 2016 and held it in 4 quarters.
  • UBS O'Connor's Corvus Pharmaceuticals position peaked at $1.7M in Q1 2016.
  • 92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.